{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Eichinger A"],"funding":["Deutsche Forschungsgemeinschaft"],"pagination":["2567-2576"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9613465"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(11)"],"pubmed_abstract":["Total body irradiation (TBI)-based conditioning is associated with superior leukemia-free survival in children with ALL undergoing HSCT. However, the risk for subsequent malignant neoplasms (SMN) remains a significant concern. We analyzed 705 pediatric patients enrolled in the prospective ALL-SCT-BFM-2003 trial and its subsequent registry. Patients >2 years received conditioning with TBI 12 Gy/etoposide (n = 558) and children ≤2 years of age or with contraindications for TBI received busulfan/cyclophosphamide/etoposide (n = 110). The 5- and 10-year cumulative incidence of SMN was 0.02 ± 0.01 and 0.13 ± 0.03, respectively. In total, 39 SMN (34 solid tumors, 5 MDS/AML) were diagnosed in 33 patients at a median of 5.8 years (1.7-13.4), exclusively in the TBI group. Of 33 affected patients,"],"journal":["Leukemia"],"pubmed_title":["Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial."],"pmcid":["PMC9613465"],"funding_grant_id":["EI 1185/1-1"],"pubmed_authors":["Peters C","Deubzer HE","Lang P","Schlegel PG","Schulz A","Bader P","Poetschger U","Eichinger A","Wawer A","Basu O","Kafa K","Kuhl JS","Lange BS","Gungor T","Corbacioglu S","Glogova E","Greil J","Beier R","Sauer MG","Strahm B","Claviez A","Gruhn B","Classen CF","Meisel R","Stachel D","Albert MH","Burkhardt B","Muller I"],"additional_accession":[]},"is_claimable":false,"name":"Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial.","description":"Total body irradiation (TBI)-based conditioning is associated with superior leukemia-free survival in children with ALL undergoing HSCT. However, the risk for subsequent malignant neoplasms (SMN) remains a significant concern. We analyzed 705 pediatric patients enrolled in the prospective ALL-SCT-BFM-2003 trial and its subsequent registry. Patients >2 years received conditioning with TBI 12 Gy/etoposide (n = 558) and children ≤2 years of age or with contraindications for TBI received busulfan/cyclophosphamide/etoposide (n = 110). The 5- and 10-year cumulative incidence of SMN was 0.02 ± 0.01 and 0.13 ± 0.03, respectively. In total, 39 SMN (34 solid tumors, 5 MDS/AML) were diagnosed in 33 patients at a median of 5.8 years (1.7-13.4), exclusively in the TBI group. Of 33 affected patients,","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-07-14T15:52:05.809Z","creation":"2024-11-09T20:29:30.381Z"},"accession":"S-EPMC9613465","cross_references":{"pubmed":["36097283"],"doi":["10.1038/s41375-022-01693-z"]}}